CSPC Pharmaceutical Group Ltd (HKG: 1093), a Chinese pharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 chemical drug, SYH2038, in advanced solid tumors.
SYH2038 is a highly selective SOS1 inhibitor, with no similar products currently available on the global market. Pre-clinical studies have demonstrated that SYH2038 exhibits high selectivity for its therapeutic targets, superior in vitro and in vivo activity, and favorable safety profiles. The drug is protected by patents both in China and internationally.- Flcube.com
